- Thinly traded micro cap Galmed Pharmaceuticals (NASDAQ:GLMD) is set for a down day after announcing disappointing results from a Phase 2a proof-of-concept study evaluating Aramchol (arachidyl amido cholanoic acid) in 50 patients with HIV-associated lipodystrophy (the body is unable to produce fat) and non-alcoholic fatty liver disease (NAFLD).
- The study, called ARRIVE, failed to met the primary endpoint of an improvement in liver fat at week 12.
- Top-line results from a Phase 2b study, ARREST, assessing Aramchol in 248 NASH patients should be available next quarter.
- Aramchol is a bile acid conjugate that the company says modulates hepatic lipid metabolism, down-regulating the three main pathologies of NASH: steatosis (abnormal retention of fats in cells), inflammation and fibrosis (scarring).
- Previously: Galmed Pharma's Aramchol shows encouraging anti-fibrotic effect in preclinical model of fatty liver disease; shares up 8% premarket (March 30, 2016)
- Now read: ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines
Original article